BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

First Hawaiian Bank grew its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) by 4.6% in the ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has earned an average recommendation of “Hold” from the seven ...

In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...

We recently published a list of 10 Firms Post Strong Gains Amid Wall Street Bloodbath. In this article, we are going to take ...

Energy is the star sector of the S&P 500 index in the early days of 2025, shaking off two consecutive years when it was a market laggard, and gaining despite Wall Street’s dim outlook for oil and gas ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2308.0, ...

Fintel reports that on January 7, 2025, BTIG initiated coverage of Hims & Hers Health (NYSE:HIMS) with a Buy recommendation.

On Wednesday, IREN Ltd (IREN) stock saw a decline, ending the day at $10.51 which represents a decrease of $-0.87 or -7.64% from the prior close of $11.38. The stock opened at $11 and touched a low of ...

BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...